Shots:
- Windward Bio via its affiliate, LE2025 Therapeutics, has entered into a licensing agreement with Qyuns to develop & commercialize WIN027 (QX027N; anti-TSLPxIL-13 bsAb)
- As per the deal, Windward will obtain exclusive rights to develop, manufacture, & commercialize WIN027 outside of China, with Qyuns receiving an upfront payment, equity, & development, regulatory, & commercial milestones, representing the total deal value of ~$700M, as well as tiered royalties
- Additionally, Windward Bio’s lead asset, WIN378 (anti-TSLP mAb), is being evaluated in the global P-II (POLARIS) trial for asthma, with initial data expected in 2026 & a P-II trial in COPD is also expected to begin in 2026
Ref: Globe newswire | Image: Windward Bio & Qyuns | Press Release
Related News: Vir Biotechnology Licenses Tobevibart & Elebsiran Combination to Norgine in EU, Australia and New Zealand
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
